We noticed you’re blocking ads

Thanks for visiting CRSToday. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://crstoday.com in your ad blocker then refresh this page.

Need help? Click here for instructions.

Digital Outsert | Sponsored by Alcon

Rising Up

The right patient selection can make all the difference with presbyopia-mitigating IOLs. Watch Neel Desai, MD, and Caroline Watson, MD, discuss their approaches to patient selection with the Clareon® PanOptix® and Vivity® IOLs and the positive impact these lenses are having on their patients’ lives.

Watch More on Eyetube

The patients in whom I have implanted these lenses have been so ecstatic. They’re amazed at the vision that they have achieved.

– Caroline Watson, MD

With PanOptix, we’re seeing an amazing level of patient satisfaction. With Clareon, we build upon that legacy.

– Neel Desai, MD

SEE FUTURE ISSUES to hear from more surgeons who are rising up with Clareon PanOptix and Vivity.

Important Product Information – Clareon® Aspheric Family of Hydrophobic Acrylic IOLs

CAUTION: Federal law restricts this device to sale by or on the order of a physician.

INDICATION: The Clareon® Aspheric Hydrophobic Acrylic IOLs include the Clareon® Aspheric and Clareon® Aspheric Toric IOLs and are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. In addition, the Clareon® Aspheric Toric IOL is indicated to correct pre-existing corneal astigmatism.

WARNINGS/PRECAUTIONS: The Clareon® IOL is intended for implantation in the capsular bag only. Physicians considering lens implantation under any of the following circumstances should weigh the potential risk/benefit ratio: Patients in whom the posterior capsule is ruptured, zonules are damaged, or primary posterior capsulotomy is planned.

Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting the IOL in a patient with any of the conditions described in the Directions for Use.

For the Clareon® Aspheric Toric IOLs, rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation.

As with any surgical procedure, there is risk involved. Potential complications accompanying cataract and/or IOL implantation surgery may include, but are not limited to, the following: lens epithelial cell on- growth, corneal endothelial cell damage, infection (endophthalmitis), toxic anterior segment syndrome (TASS), retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon, anterior uveitis, hyphema, pigment dispersion, posterior capsule opacification, transient or persistent glaucoma, and secondary surgical interventions. Secondary surgical interventions include, but are not limited to: lens repositioning, lens replacement, vitreous aspiration or iridectomy for pupillary block, wound leak repair, and retinal detachment repair.

Prior to surgery, prospective patients should be informed of the possible risks and benefits associated with this IOL as well as the risks and benefits associated with cataract surgery. After surgery, physicians should provide an implant card to patients regarding the IOL implanted.

DO NOT re-sterilize the Clareon® IOL by any method. The device is for single use only.

ATTENTION: Refer to the Directions for Use labeling for a complete list of indications, warnings and precautions.

© 2023 Alcon Inc. 7/23 US-CPO-2300043

Clareon trademark information. All other brand/product names are the trademarks of their respective owners.

1. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Directions for Use.

2. Clareon® Vivity® Extended Vision Hydrophobic IOL. Directions for Use.